Delayed pressure urticaria - Dapsone heading for first-line therapy?
Summary Background: Pressure urticaria as a subform of physical urticaria is rare and treatment is often difficult. Established therapeutic regimes include antihistamines (generally exceeding approved dosages in order to achieve a therapeutic benefit) or antihistamines combined with montelukast. Com...
Gespeichert in:
| Veröffentlicht in: | Journal der Deutschen Dermatologischen Gesellschaft 2011-11, Vol.9 (11), p.908-912 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 912 |
|---|---|
| container_issue | 11 |
| container_start_page | 908 |
| container_title | Journal der Deutschen Dermatologischen Gesellschaft |
| container_volume | 9 |
| creator | Grundmann, Sonja Alexandra Kiefer, Sabine Luger, Thomas Anton Brehler, Randolf |
| description | Summary
Background: Pressure urticaria as a subform of physical urticaria is rare and treatment is often difficult. Established therapeutic regimes include antihistamines (generally exceeding approved dosages in order to achieve a therapeutic benefit) or antihistamines combined with montelukast. Complete relief of symptoms is difficult.
Patients and methods: We used dapsone as an early therapeutic alternative in the event of treatment failure and established a standardized therapeutic regime at our clinic. We surveyed 31 patients retrospectively who had received dapsone between 2003–2009.
Results: In 74 % of patients in whom symptoms persisted despite established therapies, the results of treatment with dapsone were good or very good. Longer‐term pressure urticaria and the co‐existence of a chronic spontaneous urticaria were associated with a smaller benefit (p |
| doi_str_mv | 10.1111/j.1610-0387.2011.07749.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_900776200</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>900776200</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3219-47560413dd29fd4d08a352fdf413a5e41945caeb939e0a5f061a0ba5c182fc733</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0E4lH4BZQdq4SxHcfJAiFEoLwEQoBYWm4yBpe0CXYi2r8nodA1s5nR-J6xdAgJKES0r-NpRBMKIfBURgwojUDKOIsWG2R3_bC5nmW2Q_a8nwIwkQJskx1GpaRMil2S51jpJZZB49D7zmHQudYW2lkdhEGuG1_PMXhHXdr5W2BqFxjrfBtWtl-37-h0szzdJ1tGVx4PfvuIvFxePJ9fhXcP4-vzs7uw4IxmYSxFAjHlZckyU8YlpJoLZkrT77TAmGaxKDROMp4haGEgoRomWhQ0ZaaQnI_I0epu4-rPDn2rZtYXWFV6jnXnVQa9h4QB9Ml0lSxc7b1DoxpnZ9otFQU1KFRTNdhRgyk1KFQ_CtWiRw9_P-kmMyzX4J-zPnCyCnzZCpf_PqzyfDxMPR-ueOtbXKx57T5UIrkU6vV-rJ6u4Hac3uTqkX8DEdSNhw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>900776200</pqid></control><display><type>article</type><title>Delayed pressure urticaria - Dapsone heading for first-line therapy?</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Grundmann, Sonja Alexandra ; Kiefer, Sabine ; Luger, Thomas Anton ; Brehler, Randolf</creator><creatorcontrib>Grundmann, Sonja Alexandra ; Kiefer, Sabine ; Luger, Thomas Anton ; Brehler, Randolf</creatorcontrib><description>Summary
Background: Pressure urticaria as a subform of physical urticaria is rare and treatment is often difficult. Established therapeutic regimes include antihistamines (generally exceeding approved dosages in order to achieve a therapeutic benefit) or antihistamines combined with montelukast. Complete relief of symptoms is difficult.
Patients and methods: We used dapsone as an early therapeutic alternative in the event of treatment failure and established a standardized therapeutic regime at our clinic. We surveyed 31 patients retrospectively who had received dapsone between 2003–2009.
Results: In 74 % of patients in whom symptoms persisted despite established therapies, the results of treatment with dapsone were good or very good. Longer‐term pressure urticaria and the co‐existence of a chronic spontaneous urticaria were associated with a smaller benefit (p<0.05). No significant effects were found related to age, gender, duration of therapy, side‐effects, or Met‐Hb elevation (a tendency toward a decreased benefit was associated with middle‐age, male sex, shorter duration of therapy, observed side‐effects, and Met‐Hb elevation).
Conclusions: Therapy is well tolerated and results in a good therapeutic benefit which lasts after termination of therapy. With adequate monitoring, the use of dapsone in patients with pressure urticaria has such a good risk‐benefit ratio that we support early treatment initiation.</description><identifier>ISSN: 1610-0379</identifier><identifier>EISSN: 1610-0387</identifier><identifier>DOI: 10.1111/j.1610-0387.2011.07749.x</identifier><identifier>PMID: 21771275</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anti-Infective Agents - adverse effects ; Anti-Infective Agents - therapeutic use ; Ascorbic Acid - administration & dosage ; Chronic Disease ; chronic urticaria ; dapsone ; Dapsone - adverse effects ; Dapsone - therapeutic use ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Resistance ; drug therapy ; Drug Therapy, Combination ; Female ; Humans ; Male ; Methemoglobin - metabolism ; Middle Aged ; Pressure - adverse effects ; pressure urticaria ; Retrospective Studies ; urticaria ; Urticaria - blood ; Urticaria - drug therapy ; Urticaria - etiology</subject><ispartof>Journal der Deutschen Dermatologischen Gesellschaft, 2011-11, Vol.9 (11), p.908-912</ispartof><rights>The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin</rights><rights>The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3219-47560413dd29fd4d08a352fdf413a5e41945caeb939e0a5f061a0ba5c182fc733</citedby><cites>FETCH-LOGICAL-c3219-47560413dd29fd4d08a352fdf413a5e41945caeb939e0a5f061a0ba5c182fc733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1610-0387.2011.07749.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1610-0387.2011.07749.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21771275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grundmann, Sonja Alexandra</creatorcontrib><creatorcontrib>Kiefer, Sabine</creatorcontrib><creatorcontrib>Luger, Thomas Anton</creatorcontrib><creatorcontrib>Brehler, Randolf</creatorcontrib><title>Delayed pressure urticaria - Dapsone heading for first-line therapy?</title><title>Journal der Deutschen Dermatologischen Gesellschaft</title><addtitle>J Dtsch Dermatol Ges</addtitle><description>Summary
Background: Pressure urticaria as a subform of physical urticaria is rare and treatment is often difficult. Established therapeutic regimes include antihistamines (generally exceeding approved dosages in order to achieve a therapeutic benefit) or antihistamines combined with montelukast. Complete relief of symptoms is difficult.
Patients and methods: We used dapsone as an early therapeutic alternative in the event of treatment failure and established a standardized therapeutic regime at our clinic. We surveyed 31 patients retrospectively who had received dapsone between 2003–2009.
Results: In 74 % of patients in whom symptoms persisted despite established therapies, the results of treatment with dapsone were good or very good. Longer‐term pressure urticaria and the co‐existence of a chronic spontaneous urticaria were associated with a smaller benefit (p<0.05). No significant effects were found related to age, gender, duration of therapy, side‐effects, or Met‐Hb elevation (a tendency toward a decreased benefit was associated with middle‐age, male sex, shorter duration of therapy, observed side‐effects, and Met‐Hb elevation).
Conclusions: Therapy is well tolerated and results in a good therapeutic benefit which lasts after termination of therapy. With adequate monitoring, the use of dapsone in patients with pressure urticaria has such a good risk‐benefit ratio that we support early treatment initiation.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Infective Agents - adverse effects</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Ascorbic Acid - administration & dosage</subject><subject>Chronic Disease</subject><subject>chronic urticaria</subject><subject>dapsone</subject><subject>Dapsone - adverse effects</subject><subject>Dapsone - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance</subject><subject>drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Methemoglobin - metabolism</subject><subject>Middle Aged</subject><subject>Pressure - adverse effects</subject><subject>pressure urticaria</subject><subject>Retrospective Studies</subject><subject>urticaria</subject><subject>Urticaria - blood</subject><subject>Urticaria - drug therapy</subject><subject>Urticaria - etiology</subject><issn>1610-0379</issn><issn>1610-0387</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtOwzAQRS0E4lH4BZQdq4SxHcfJAiFEoLwEQoBYWm4yBpe0CXYi2r8nodA1s5nR-J6xdAgJKES0r-NpRBMKIfBURgwojUDKOIsWG2R3_bC5nmW2Q_a8nwIwkQJskx1GpaRMil2S51jpJZZB49D7zmHQudYW2lkdhEGuG1_PMXhHXdr5W2BqFxjrfBtWtl-37-h0szzdJ1tGVx4PfvuIvFxePJ9fhXcP4-vzs7uw4IxmYSxFAjHlZckyU8YlpJoLZkrT77TAmGaxKDROMp4haGEgoRomWhQ0ZaaQnI_I0epu4-rPDn2rZtYXWFV6jnXnVQa9h4QB9Ml0lSxc7b1DoxpnZ9otFQU1KFRTNdhRgyk1KFQ_CtWiRw9_P-kmMyzX4J-zPnCyCnzZCpf_PqzyfDxMPR-ueOtbXKx57T5UIrkU6vV-rJ6u4Hac3uTqkX8DEdSNhw</recordid><startdate>201111</startdate><enddate>201111</enddate><creator>Grundmann, Sonja Alexandra</creator><creator>Kiefer, Sabine</creator><creator>Luger, Thomas Anton</creator><creator>Brehler, Randolf</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201111</creationdate><title>Delayed pressure urticaria - Dapsone heading for first-line therapy?</title><author>Grundmann, Sonja Alexandra ; Kiefer, Sabine ; Luger, Thomas Anton ; Brehler, Randolf</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3219-47560413dd29fd4d08a352fdf413a5e41945caeb939e0a5f061a0ba5c182fc733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Infective Agents - adverse effects</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Ascorbic Acid - administration & dosage</topic><topic>Chronic Disease</topic><topic>chronic urticaria</topic><topic>dapsone</topic><topic>Dapsone - adverse effects</topic><topic>Dapsone - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance</topic><topic>drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Methemoglobin - metabolism</topic><topic>Middle Aged</topic><topic>Pressure - adverse effects</topic><topic>pressure urticaria</topic><topic>Retrospective Studies</topic><topic>urticaria</topic><topic>Urticaria - blood</topic><topic>Urticaria - drug therapy</topic><topic>Urticaria - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grundmann, Sonja Alexandra</creatorcontrib><creatorcontrib>Kiefer, Sabine</creatorcontrib><creatorcontrib>Luger, Thomas Anton</creatorcontrib><creatorcontrib>Brehler, Randolf</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal der Deutschen Dermatologischen Gesellschaft</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grundmann, Sonja Alexandra</au><au>Kiefer, Sabine</au><au>Luger, Thomas Anton</au><au>Brehler, Randolf</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Delayed pressure urticaria - Dapsone heading for first-line therapy?</atitle><jtitle>Journal der Deutschen Dermatologischen Gesellschaft</jtitle><addtitle>J Dtsch Dermatol Ges</addtitle><date>2011-11</date><risdate>2011</risdate><volume>9</volume><issue>11</issue><spage>908</spage><epage>912</epage><pages>908-912</pages><issn>1610-0379</issn><eissn>1610-0387</eissn><abstract>Summary
Background: Pressure urticaria as a subform of physical urticaria is rare and treatment is often difficult. Established therapeutic regimes include antihistamines (generally exceeding approved dosages in order to achieve a therapeutic benefit) or antihistamines combined with montelukast. Complete relief of symptoms is difficult.
Patients and methods: We used dapsone as an early therapeutic alternative in the event of treatment failure and established a standardized therapeutic regime at our clinic. We surveyed 31 patients retrospectively who had received dapsone between 2003–2009.
Results: In 74 % of patients in whom symptoms persisted despite established therapies, the results of treatment with dapsone were good or very good. Longer‐term pressure urticaria and the co‐existence of a chronic spontaneous urticaria were associated with a smaller benefit (p<0.05). No significant effects were found related to age, gender, duration of therapy, side‐effects, or Met‐Hb elevation (a tendency toward a decreased benefit was associated with middle‐age, male sex, shorter duration of therapy, observed side‐effects, and Met‐Hb elevation).
Conclusions: Therapy is well tolerated and results in a good therapeutic benefit which lasts after termination of therapy. With adequate monitoring, the use of dapsone in patients with pressure urticaria has such a good risk‐benefit ratio that we support early treatment initiation.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21771275</pmid><doi>10.1111/j.1610-0387.2011.07749.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1610-0379 |
| ispartof | Journal der Deutschen Dermatologischen Gesellschaft, 2011-11, Vol.9 (11), p.908-912 |
| issn | 1610-0379 1610-0387 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_900776200 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Aged, 80 and over Anti-Infective Agents - adverse effects Anti-Infective Agents - therapeutic use Ascorbic Acid - administration & dosage Chronic Disease chronic urticaria dapsone Dapsone - adverse effects Dapsone - therapeutic use Dose-Response Relationship, Drug Drug Administration Schedule Drug Resistance drug therapy Drug Therapy, Combination Female Humans Male Methemoglobin - metabolism Middle Aged Pressure - adverse effects pressure urticaria Retrospective Studies urticaria Urticaria - blood Urticaria - drug therapy Urticaria - etiology |
| title | Delayed pressure urticaria - Dapsone heading for first-line therapy? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A49%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Delayed%20pressure%20urticaria%20-%20Dapsone%20heading%20for%20first-line%20therapy?&rft.jtitle=Journal%20der%20Deutschen%20Dermatologischen%20Gesellschaft&rft.au=Grundmann,%20Sonja%20Alexandra&rft.date=2011-11&rft.volume=9&rft.issue=11&rft.spage=908&rft.epage=912&rft.pages=908-912&rft.issn=1610-0379&rft.eissn=1610-0387&rft_id=info:doi/10.1111/j.1610-0387.2011.07749.x&rft_dat=%3Cproquest_cross%3E900776200%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=900776200&rft_id=info:pmid/21771275&rfr_iscdi=true |